DRKY - ETF AI Analysis
Top Page
VistaShares Target 15 DRUKMacro Distribution ETF (DRKY)
Rating:67Neutral
Price Target:―
Positive Factors
Strong Leading Holdings
Several of the largest positions, including Natera, TSMC, YPF, Roku, and STMicroelectronics, have shown strong gains this year, helping support the ETF’s overall results.
Recent Performance Momentum
The fund has delivered solid gains over the last one and three months, indicating improving short-term momentum despite a slightly negative year-to-date result.
Targeted Sector Exposure
A heavy tilt toward health care and meaningful exposure to technology and consumer sectors gives investors focused access to areas with strong growth potential.
Negative Factors
High Single-Stock Concentration
Natera alone makes up a very large share of the portfolio, which increases the risk that a setback in this one company could significantly hurt the ETF.
Sector Concentration Risk
Nearly half of the fund is in health care, so negative news or regulation in that sector could have an outsized impact on performance.
High Expense Ratio
The ETF charges a relatively high fee, which can eat into returns over time compared with lower-cost alternatives.
DRKY vs. SPDR S&P 500 ETF (SPY)
AUM21.09M
RegionNorth America
Expense Ratio0.95%
Beta1.01
IssuerVistaShares
Inception DateOct 08, 2025
Dividend Yield14.57%
Asset ClassEquity
Index TrackedNo Underlying Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume6,181
30 Day Avg. Volume9,453
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
28.12Price Target Upside― Downside
Rating ConsensusStrong Buy
Number of Analyst Covering21
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
DRKY Summary
DRKY, the VistaShares Target 15 DRUKMacro Distribution ETF, is an actively managed fund that follows a “total U.S. market” theme, guided by the publicly disclosed stock picks of famed investor Stanley Druckenmiller’s family office. It mainly holds health care and technology companies, with notable names like Roku and Teva Pharmaceutical, and aims to provide both broad stock exposure and high monthly income. Someone might invest in DRKY for diversification across many U.S. companies plus the potential for steady payouts. A key risk is that it’s heavily tilted toward health care and can rise or fall significantly with the overall stock market.
How much will it cost me?The expense ratio for the VistaShares Target 15 DRUKMacro Distribution ETF (Ticker: DRKY) is 0.95%, meaning you’ll pay $9.50 per year for every $1,000 invested. This is higher than average because the fund is actively managed, using sophisticated strategies and insights from the Duquesne Family Office to maximize income and returns.
What would affect this ETF?The DRKY ETF, with its strong focus on U.S. equities and significant exposure to healthcare and technology sectors, could benefit from advancements in medical innovation and tech growth, especially if economic conditions remain favorable for these industries. However, its reliance on derivative strategies and concentration in specific sectors may pose risks during periods of market volatility or regulatory changes affecting healthcare and technology. Broader economic factors, such as interest rate hikes or a slowdown in consumer spending, could also impact the ETF's performance negatively.
DRKY Top 10 Holdings
DRKY is leaning heavily on health care and tech, with Natera as the clear star—its rising share price and big weight make it the main engine for the fund. Semiconductor names like TSMC and STMicroelectronics are more of a mixed bag, with recent softness taking a bit of shine off earlier gains. On the income and energy side, YPF and BBB Foods are quietly pulling their weight, while Insmed looks more like a passenger than a driver. Despite a few global names, the fund’s story is still anchored in a U.S.-centric, growth-tilted playbook.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Natera | 26.64% | $5.57M | $57.76B | 136.73% | 73 Outperform | |
| TSMC | 9.64% | $2.02M | $2.07T | 61.52% | 81 Outperform | |
| STMicroelectronics | 7.86% | $1.64M | $46.58B | 92.03% | 57 Neutral | |
| BBB Foods, Inc. Class A | 4.43% | $925.65K | $6.04B | 124.97% | 60 Neutral | |
| Alphabet Class A | 4.42% | $924.36K | $4.28T | 48.65% | 85 Outperform | |
| Amazon | 4.41% | $922.49K | $2.83T | 21.29% | 71 Outperform | |
| YPF Sociedad Anonima | 4.34% | $906.53K | $20.90B | 89.40% | 54 Neutral | |
| Seagate Tech | 4.06% | $849.21K | $178.05B | 265.24% | 68 Neutral | |
| Insmed | 3.86% | $807.56K | $21.97B | -38.03% | 43 Neutral | |
| Fox | 3.83% | $800.22K | $24.88B | 8.98% | 77 Outperform |
DRKY Technical Analysis
Positive
―
Price Trends
21.28
Positive
20.30
Positive
19.52
Positive
Market Momentum
0.14
Positive
46.35
Neutral
13.82
Positive
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For DRKY, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 21.88, equal to the 50-day MA of 21.28, and equal to the 200-day MA of 19.52, indicating a neutral trend. The MACD of 0.14 indicates Positive momentum. The RSI at 46.35 is Neutral, neither overbought nor oversold. The STOCH value of 13.82 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DRKY.
DRKY Peer Comparison
Comparison Results
Performance Comparison
DRKY
VistaShares Target 15 DRUKMacro Distribution ETF
21.47
4.33
25.26%
BAMD
Brookstone Dividend Stock ETF
―
―
―
STNC
Stance Equity ESG Large Cap Core ETF
―
―
―
PFOE
Pathfinder Focused Opportunities ETF
―
―
―
SOVF
Sovereign's Capital Flourish Fund
―
―
―
VAMO
Cambria Value & Momentum ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents